Perceptive Advisors-backed Arya Sciences Acquisition III, a SPAC, completed the merger with Nautilus Biotechnology, a single-molecule protein analysis platform provider, in a $900m deal. In addition to the c. $150m provided by Arya III, a group of healthcare investors will provide c. $200m through PIPE investment. Investors in the PIPE include lead investor Perceptive Advisors, as well as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, Casdin Capital and existing Nautilus Biotechnology shareholders including Andreessen Horowitz, Madrona Venture Group, and Vulcan Capital. Nautilus shareholders are expected to own 70% of the company. “Our long-standing relationship with Perceptive Advisors, combined with a strong syndicate of other investors, make us confident that this transaction aligns well with our goals of unlocking what we believe to be a significant opportunity in biological science, and creating long-term shareholder value," Sujal Patel, Nautilus CEO.